Why Medical and Safety Review Is One of the Last Manual Workflows in Clinical Trials

It is Tuesday morning. You have a data cut from last night, three studies to review before end of week, and a patient-level safety flag that needs an answer before this afternoon’s call with the sponsor. 

So you open the EDC, pull the adverse event listing, cross-reference the lab data in a separate system, check the concomitant medications in a third, and start rebuilding the patient picture from scratch, much like you did in the last review cycle. 

Medical and safety review is one of the most consequential workflows in clinical development. Yet in many organizations, one of the least modernized. 

Medical & Safety Review Is Mandatory. The Workflow Hasn’t Kept Up. 

Every clinical trial conducted under ICH-GCP requires medical and Safety review. It is not optional. It is not a best practice. It is a regulatory requirement and it runs continuously, from first patient in to last patient out. 

Medical Monitors provide ongoing medical oversight, assessing patient-level anomalies, protocol deviations, and dosing decisions as they arise. Safety reviewers focus on systematic evaluation of adverse events, signal detection, and regulatory reportability across the dataset. Together, their decisions directly affect patient safety, study continuity, and inspection readiness.  

And yet, across many sponsors, this mandatory process still relies on: 

• Direct EDC navigation  

• Excel-based tracking  

• Programming requests routed through Data Management  

• Email-driven follow-up with little or no audit traceability  

This is not a criticism of the people doing the work. It is a description of the infrastructure surrounding it, and the growing gap between how important the work is and how it is actually executed. 

The Real Problem Is the Gap Between Event and Insight 

Before a reviewer can interpret anything, they first must assemble the context around it. 

A single patient review may require pulling together medical history, lab results from multiple sources, adverse event data, concomitant medications, vital signs, and prior therapy records, each managed by a different function, refreshed at a different cadence, and stored in a different place. 

That assembly takes time. And while it is happening, the gap between when something occurred and when a reviewer fully understands it continues to grow. 

The event-to-insight gap is not fundamentally a data problem. It is a workflow problem. And in clinical trials, delay creates risk. 

When review cycles run weekly or fortnightly, as they often do in manual environments, a safety signal that emerged on day one of a data cut may not reach a reviewer’s attention until day twelve. That is twelve days during which the signal existed but nobody acted on it. 

Multiply that across a portfolio of studies, and the cumulative oversight gap becomes significant. 

Medical Review Happens in an Environment of Constant Interpretation 

Medical review is not a linear process. Reviewers are constantly evaluating whether: 

• Something is meaningful  

• It represents a broader pattern  

• It warrants escalation  

• It has already been reviewed elsewhere  

At the same time, they are managing increasing study complexity, fragmented workflows, and growing data volumes spread across multiple systems. 

This is where pressure builds. Not because of the science itself, but because of the operational burden surrounding it. 

Without a structured workflow, review approaches vary. Prioritization differs. Follow-up becomes disconnected. Documentation becomes difficult to reconstruct. Even highly experienced reviewers may focus on different signals or apply different thresholds to the same data. 

This is not simply an efficiency problem. Increasingly, it becomes a quality and oversight problem. 

Because expectations around Medical & Safety Review have changed. 

Regulators Are No Longer Just Asking Whether Review Happened 

Under modern GCP expectations, reinforced by ICH E6(R3), organizations must increasingly demonstrate that review was: 

• Timely  

• Proportionate  

• Justified  

• Traceable  

That is a materially different standard from simply confirming that a Medical Monitor was assigned to a study. 

Timeliness is difficult to demonstrate when review cycles depend on manual data assembly. Proportionality is hard to evidence when there are no structured rules defining how reviewers prioritize their attention. Traceability becomes difficult when decisions live across spreadsheets, emails, and individual reviewer memory. 

The industry has already gone through this evolution in other areas of clinical oversight. Risk-Based Quality Management has moved from concept to regulatory expectation. Site monitoring has shifted from exhaustive SDV toward adaptive, risk-based models. 

Medical & Safety Review is now following the same trajectory, moving from fragmented activity toward structured, evidence-based workflow execution. 

The Fix Is Not Better Dashboards. It Is a Different Workflow. 

Many attempts to modernize Medical & Safety Review start with visibility. 

More dashboards. More visualizations. More access to data. 

Those improvements matter. But they do not solve the core problem. 

The real issue is not that reviewers cannot see the data. It is that they spend the first hour of every review cycle rebuilding the context they need to begin reviewing it. 

A modern MSR workflow changes the starting point. 

Instead of opening a blank EDC and assembling a patient picture from scratch, a reviewer begins with a unified view that consolidates every relevant data source and surfaces changes since the last review cycle, so reviewers begin with context already assembled. 

They do not review everything. They review what changed while retaining full access to the broader patient context needed for sound clinical judgment. 

When something requires action, it happens inside the same workflow. A query is raised directly, with full context attached, routed to the right person, with a record of what was seen, what was decided, and why. The audit trail is captured as a natural output of the review process, not reconstructed before inspection. 

Review rules configured once and applied consistently ensure that the same signals are identified every time, regardless of which reviewer is assigned to the study that week. Consistency becomes a function of the workflow itself, not a function of individual memory and interpretation. 

When review is structured, traceable, and built around change rather than static listings, the entire workflow compresses. Events reach insight faster. Action follows immediately. Evidence accumulates continuously. 

The Standard Has Changed. The Workflow Should Too. 

Medical & Safety Review will always depend on experienced clinical professionals making informed judgments. 

That part is not changing. 

What is changing is the expectation that those judgments happen within workflows that are faster, more consistent, fully traceable, and capable of scaling across increasingly complex studies. 

Manual review processes were never designed for the volume and velocity of modern clinical trial data. They were built for a world where a single reviewer could hold the context of one study in their head, where data volumes were manageable by spreadsheet, and where regulatory scrutiny focused primarily on whether review occurred rather than how it was executed. 

That world has changed. The workflow needs to catch up. 

Because ultimately: 

• Patient safety depends on early insight  

• Trial success depends on timely action  

• Regulatory confidence depends on clear evidence  

And all three are shaped by how Medical & Safety Review is executed, not simply whether it is. 

Want to see what a modern medical and safety review workflow looks like in practice?
Download Medical & Safety Review: From Event to Insight, a practical guide to building a faster, more consistent, and audit-ready clinical data review workflow.